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Highlights 3 
 First method employing dialysis membrane for physical separation between Tenax 4 
TA® and dust 5 
 Tenax TA® used as an absorption sink trapped in dialysis membrane mimics the 6 
situation in vivo 7 
 CE-PBET performance was tested under different Tenax TA® loadings (0.25, 0.5 & 8 
0.75 g) 9 
 Two to three-fold bioaccessibility increase with Tenax TA® inclusion for all PBDEs 10 
 Colon sorption to Tenax TA® was similar to small intestine for BDE28, but was 11 
higher than small intestine sorption for other PBDEs  12 
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Abstract  28 
Human uptake of flame retardants (FRs) such as polybrominated diphenyl ethers (PBDEs) 29 
via indoor dust ingestion is commonly considered as 100% bioaccessible, leading to potential 30 
risk overestimation. Here, we present a novel in vitro colon-extended physiologically-based 31 
extraction test (CE-PBET) with Tenax TA® as an absorptive “sink” capable to enhance 32 
PBDE gut bioaccessibility. A cellulose-based dialysis membrane (MW cut-off 3.5kDa) with 33 
high pH and temperature tolerance was used to encapsulate Tenax TA®, facilitating efficient 34 
physical separation between the absorbent and the dust, while minimizing re-absorption of 35 
the ingested PBDEs to the dust particles. As a proof of concept, PBDE-spiked indoor dust 36 
samples (n=3) were tested under four different conditions; without any Tenax TA® addition 37 
(control) and with three different Tenax TA® loadings (i.e. 0.25, 0.5 or 0.75 g). Our results 38 
show that in order to maintain a constant sorptive gradient for the low MW PBDEs 0.5 g of 39 
Tenax TA® are required in CE-PBET.. Tenax TA® inclusion (0.5 g) resulted in 40%  gut 40 
bioaccessibility c.for BDE153 and BDE183, whereas greater bioaccessibility values were 41 
seen for less hydrophobic PBDEs such as BDE28 and BDE47 (̴ 60%). When tested using 42 
SRM 2585, our new Tenax TA® method did not present any statistically significant effect 43 
(p>0.05) between non- spiked and PBDE- spiked SRM 2585 treatments. Our study describes 44 
an efficient method where due to the sophisticated design, Tenax TA® recovery and 45 
subsequent bioaccessibility determination can be simply and reliably achieved.   46 
 47 
Keywords: bioaccessibility, Tenax TA®, dialysis membrane, PBDEs, indoor dust  48 
49 
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1. Introduction 50 
Despite the strict legislative measures on the use of Penta-BDE and Octa-BDE formulations 51 
in both the EU and USA in consumer products (e.g. carpets, electronic appliances and 52 
furniture polyurethane foam) (Dodson et al., 2012; European Commission, 2003) and their 53 
listing as persistent organic pollutants (POPs) under the Stockholm Convention (Stockholm 54 
Convention, 2009a, 2009b), polybrominated diphenyl ethers (PBDEs) are legacy flame 55 
retardants (FRs) being detected in considerable levels in indoor dust from China (Cao et al., 56 
2014; Sun et al., 2016), France (Raffy et al., 2017), the UK (Kademoglou et al., 2017; Tao et 57 
al., 2016), the Czech Republic, USA and Canada (Venier et al., 2016). Under this regime, 58 
human health concerns remain a critical issue, given the well-known PBDE potential to 59 
induce endocrine and thyroid disruption (Legler, 2008) and neurodevelopmental disorders in 60 
children (Bellinger, 2013; Costa and Giordano, 2007).  61 
Total pollutant concentration of a contaminated solid matrix is perceived as the bioavailable 62 
fraction after ingestion and it is frequently used in human risk and exposure assessment 63 
(Semple et al., 2004). However, the assumption that 100% of the ingested toxicant within a 64 
matrix being available is unrealistic (Collins et al., 2015). Animal bioavailability studies (e.g. 65 
rodents or swine) are representative of the in vivo situation, but are often hindered due to 66 
financial and ethical restrictions (Oomen et al., 2003; Ruby et al., 2002). To avoid risk 67 
overestimation, bioaccessibility, i.e. the maximal fraction of an organic pollutant released 68 
from an ingested matrix (e.g. dust) into the gastro-intestinal tract (GIT) fluids of the organism 69 
has been proposed as a more realistic but conservative approach in human exposure 70 
assessment of persistent organic pollutants (POPs), serving as a surrogate to bioavailability 71 
(Brandon et al., 2006; Dean and Ma, 2007; Oomen et al., 2000). Several physiologically-72 
based extraction tests (PBET) have been proposed to assess organic pollutant release and 73 
uptake from an ingested matrix via the GIT fluids in vitro (Brandon et al., 2006; Cave et al., 74 
2010; Gouliarmou and Mayer, 2012; Tilston et al., 2011; Van de Wiele et al., 2004), as a 75 
substitute to in vivo studies (James et al., 2011) or for high-throughput estimates of 76 
bioaccessibility when animal studies are not feasible (Rodríguez-Navas et al., 2017; Ruby et 77 
al., 1996). Due to the non-polar and hydrophobic nature of hydrophobic organic compounds 78 
(HOCs) such as PBDEs, sorption to indoor dust is likely to occur via volatilisation, abrasion 79 
or fragmentation (Cao et al., 2014; García-Alcega et al., 2016), marking dust ingestion as a 80 
potential major route of exposure to FRs for humans (Alves et al., 2014; Jones-Otazo et al., 81 
2005). Hence, in vitro bioaccessibility studies have been deployed, assessing human exposure 82 
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to contaminated indoor dust on a wide spectrum of HOCs including brominated flame 83 
retardants (BFRs) (Abdallah et al., 2012), organophosphate FR (OPFRs) (He et al., 2016; 84 
Quintana et al., 2017), pesticides and polychlorinated biphenyls (PCBs) (Ertl and Butte, 85 
2012) and polybrominated diphenyl ethers (PBDEs) (Yu et al., 2012). However, the lack of 86 
an adsorption sink in the various test formats may lead to risk underestimation due to the 87 
absence of constant concentration gradient (Collins et al., 2015). Sink conditions better 88 
mimic the sorption/desorption processes in the human GIT in vivo and, coupled with the 89 
lipid-rich environment of the GI lumen and a long matrix:fluid contact time, may improve the 90 
bioaccessibility estimates of HOCs, such as PBDEs (Collins et al., 2015; Zhang et al., 2015, 91 
2016).  92 
A colon-extended PBET system (CE-PBET) with a carbohydrate-rich colon compartment as 93 
a “sink”, favouring polycyclic aromatic hydrocarbons (PAHs) desorption from soil has been 94 
described (Tilston et al., 2011). Strong adsorbents  such as silicone-activated contaminant 95 
traps, cyclodextrins and silicone rods have also been proposed as “absorption sink” materials 96 
in PBET systems, to improve bioaccessibility estimates for PAH-contaminated soil and 97 
biochar (Gouliarmou et al., 2013; Mayer et al., 2016; Zhang et al., 2015). As part of the 98 
International Organization for Standardization (ISO) guideline on bioavailability, an extended 99 
(20h) Tenax-based extraction method achieved increased mobilisation (i.e. bioaccessibility) 100 
of HOCs from soils and sediments onto this infinite sink and has been proposed for 101 
standarisation (ISO, 2015; Ortega-Calvo et al., 2015). Tenax TA® is a versatile absorption 102 
sink with large surface area and high sorption capacity for HOCs and was thus used as an 103 
“infinite” sink in PBET systems, studying the uptake of FRs and PAHs via indoor dust (Fang 104 
and Stapleton, 2014) and soil (Li et al., 2015), respectively. Cornelissen et al (1997) 105 
employed Tenax TA® studying sorption/desorption kinetics of PAHs, alkylbenzenes and 106 
PCBs from dredged sediments; the sink captured the organic pollutants from the solid matrix 107 
but the Tenax TA® beads adhered to the glassware with consequent problems for physical 108 
separation and recovery of Tenax TA® from the matrix (Cornelissen et al., 1997). The 109 
variability in Tenax TA® mass recovery, its separation from the matrix and the design of an 110 
appropriate vessel for Tenax TA® inclusion (e.g. stainless steel net) during PBET incubation 111 
has discouraged further applications of Tenax TA® in environmental exposure studies (Li et 112 
al., 2016; Mayer et al., 2016). In the work presented here, we describe a novel in vitro 113 
method capable to overcome the aforementioned challenges concerning physical separation 114 
and recovery of Tenax TA® from the matrix, while facilitating its successful inclusion and 115 
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performance as an adsorption sink in a previously established bioaccessibility test, namely 116 
CE-PBET, for the assessment of oral bioaccessibility of PBDEs from indoor dust.  117 
To separate aqueous and solid matrices, a regenerated cellulose (RC) dialysis tubing method 118 
was employed, studying the sorption and dissolution of perchloroethane and PAHs from clay-119 
rich materials and sewage sludges, respectively (Allen-King et al., 1995; Woolgar and Jones, 120 
1999). RC membranes present high pH and temperature tolerances, carry no fixed charge and 121 
are highly resistant to halogenated hydrocarbons, such as PBDEs (Pollard, 1987). Tubing 122 
characteristics including length, width, membrane sealing method and molecular weight cut 123 
off (MWCO) have been evaluated.  For example, 2.5 g of contaminated sewage sludge were 124 
introduced into 10 cm of dialysis tubing with a 3.5 kDa MWCO (Woolgar and Jones, 1999). 125 
Alternatively, 20 cm of dialysis tubing (29 mm width; 12-14 kDa MWCO) was used to 126 
ensure that at least 30% of the analyte mass would remain in the solid phase after 127 
equilibration (Allen-King et al., 1995). The solid material in the tubing was then introduced 128 
inside glass bottles with synthetic groundwater spiked with the HOCs of interest. During 129 
equilibration, all non-settling particles were retained inside the dialysis membrane, while 130 
dissolved organic pollutants could permeate through the membrane and equilibrate across the 131 
dialysis tubing by passive diffusion (Allen-King et al., 1995).  132 
Our study aims are to systematically (a) develop an efficient method to separate Tenax TA® 133 
and indoor dust as a matrix whilst enabling desorption of PBDEs to the Tenax TA® and (b) 134 
optimise Tenax TA® as an absorption sink for PBDEs in a colon-extended gastro-intestinal 135 
bioaccessibility in vitro system (CE-PBET). 136 
2. Materials and methods 137 
2.1 Target analytes and indoor dust  138 
An indoor dust sample was collected in 2013 from a pre-existing vacuum cleaner bag in an 139 
office at Reading (UK) and was used during method development tests and the results are 140 
presented in sections 3.1 and 3.2. The dust sample was sieved to <250 μm, a particle cut off 141 
likely to be ingested by humans (Yu et al., 2012), using a  hexane-washed, metallic sieve and 142 
stored in hexane-washed, amber glass bottles at +4 oC. Concentrations of all target analytes in 143 
all dust samples were determined using methods described elsewhere (Kademoglou et al., 144 
2017). Briefly, 30 mg of dust was extracted with 2.5 mL hexane:acetone (3:1) using ultra-145 
sonication extraction for 10 min and vortexing for 1 min three times. The combined extract 146 
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was concentrated to 1 mL and loaded on aminopropyl (NH2) silica cartridges (500 mg, 3 mL, 147 
Agilent, USA) and further eluted with 10 mL hexane. The eluate was then further 148 
concentrated, following a clean-up on an acidified silica cartridge (5%, 1 g, 6 mL) and elution 149 
with 12 mL dichloromethane. The dust extracts were then evaporated, reconstituted with 100 150 
μL of iso-octane and filtered using a micro centrifuge filter lined with 0.45 μm pore size 151 
nylon filter (1.5 mL volume capacity) . Finally, the extracts were transferred to injection vials 152 
and analyzed on GC-ECNI-MS. Standard reference material for indoor dust SRM 2585 153 
(organic contaminants in house dust), purchased from the US National Institute of Standards 154 
and Technology (NIST, USA), was used to assess method performance and the results are 155 
presented in section 3.3. . Both SRM 2585 (used for method  performance assessment; 0.5 g) 156 
and dust samples (0.5 g) (used for method development) were spiked at environmentally 157 
relevant concentrations (200 ng; 200L of PBDEs native standard mix 1 ng/L prepared in 158 
iso-octane) and the validity of the spiking was confirmed analytically for both the SRM 2585 159 
and the dust (Table SI  2). After spiking, samples were shaken for 2h on an orbital shaker and 160 
allowed to stand inside a fumehood for 6h before the gastro-intestinal extraction for the 161 
solvent to evaporate, thus facilitating compound interactions with the matrix (Ballesteros-162 
Gómez et al., 2016).  163 
2.2 Dialysis membrane  164 
Approximately 16 cm of standard grade, flexible and transparent regenerated cellulose (RC) 165 
dialysis membrane with 3.5 kDa MWCO and 18 mm flat width (1.1mL/cm) (Spectra/Por™ 3, 166 
SpectrumLabs Inc., USA) was used to encapsulate the Tenax TA® beads. The membrane 167 
length and flat width were selected for the sample volume to be added in the membrane using 168 
an online tool provided by SpectrumLabs Inc. 169 
(http://www.spectrumlabs.com/dialysis/dtCalc.html), allowing for tube sealing with 19 mm 170 
metallic clips. MWCO selection for the RC membrane is primarily governed by the 171 
molecular weight (MW) of the biological molecules of the GI compartments and the target 172 
analytes of our study. To maximize the rate of dialysis, the membrane with the largest 173 
MWCO which will not cause excess loss of the desired analytes was used. Hence, the 174 
MWCO was selected to be over three-fold higher of the MW of the heaviest target analyte 175 
studied here (i.e. BDE183; MW= 722) (SpectrumLabs Inc., personal communication). The 176 
diffusion of PBDEs across the membrane was aided by the addition of 10 mL of GIT fluid 177 
(i.e. stomach, small intestine, colon) inside the RC membrane/Tenax TA® system.  178 
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2.3 Gastro-intestinal Extraction 179 
The gastro-intestinal extraction test involved three compartments, namely stomach (1h; 180 
pH=2.5), small intestine (SI) (4h; pH=7) and colon (16h; pH=6.5) tested in sequential mode 181 
(Fig. 1). Fed CE-PBET conditions were achieved by the addition of dietary components such 182 
as mucin, lipid-rich carbohydrates and bile salts into stomach, SI and colon incubations as 183 
described in Table SI-3 according to (Tilston et al., 2011) and all media were prepared in 184 
deionised H2O (dH2O). All experiments were conducted in triplicate. Gut media aliquots (80 185 
mL) were added into clean, amber 100 mL Duran® glass bottles, sealed with PTFE-lined 186 
screw caps and stored at -20oC prior use if necessary. Tenax TA® beads were cleaned prior 187 
use to remove fine particles by ultrasonication with 40 mL acetone (x2), 40 mL 188 
acetone:hexane 1:1 (x2) and 40 mL hexane (x 2) for 10 min in each sonication step. Tenax® 189 
TA was then allowed to air-dry at 105 oC overnight and was stored in a hexane-washed, 190 
Duran® bottle inside a desiccator.  A short video demonstration of the Tenax TA® inclusion 191 
in the RC dialysis membrane is available online 192 
https://figshare.com/s/e7312fa7d177b35bc7d0  (video used for demonstration purposes only; 193 
the RC membrane is sealed using 19 mm metallic clips; see below). Before employment, the 194 
RC dialysis membrane was soaked in ultra-pure H2O at room temperature for 45 min under 195 
continuous stirring to remove any preservatives such as glycerine and sodium azide. The RC 196 
membrane was then thoroughly rinsed with dH2O and one side sealed with a 19 mm hexane-197 
washed, metallic clip. Using a small glass funnel, Tenax TA® (0.5 g) was added inside the 198 
RC membrane, followed by 10 mL of stomach medium. The tubing was then sealed using 199 
another metallic clip. Then, 0.5 g of indoor dust were added in the remaining 70 mL of 200 
stomach fluid and the RC membrane/Tenax TA® system was introduced to the bottle (Fig 201 
1A). A solid-to-liquid (S/L) ratio 1:140 was achieved, thus preventing any bioaccessibility 202 
underestimation due to poor dissolution of contaminants from dust (Abdallah et al., 2012; 203 
Dean and Ma, 2007). The bottles were placed at 45o angle inside a temperature-controlled 204 
waterbath at 37 oC and rotated at 130 rpm for 1h, mimicking the GIT peristaltic movement. 205 
After 1 h, the samples were removed from the waterbath and, due to the continuous character 206 
of CE-PBET, stomach fluid was converted to small intestine media (SI) by addition of bile 207 
salts (0.5 g/L) and pancreatine (1.78 g/L) with pH adjusted to 7 using saturated NaHCO3. The 208 
small intestine incubation continued as above for 4h (Fig 1 B). The stomach medium was 209 
converted to small intestine only outside the membrane, given the assumption that bile salts 210 
and pancreatine would permeate to the inner barrier of the RC membrane during the 4-h 211 
small intestine incubation step in order to reach a pH equilibrium between inside and outside 212 
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of the RC membrane/Tenax TA® system to sustain sorption/desorption by passive diffusion. 213 
According to Spectrum Labs Inc. (USA) instructions to users, a first-order permeability rate 214 
is observed provided that the RC tubing system is well stirred and the solvent (in our case gut 215 
fluid) is changed several times during the dialysis procedure (Spectrum Labs Inc., personal 216 
communication). The RC membrane/Tenax TA® system was then removed from the bottle 217 
and was allowed to sediment for 15 min. Due to its hydrophobic character, Tenax TA® floats 218 
on top of the small intestine fluid inside the membrane (Fig. SI 1). Tenax TA® was trapped 219 
on the one side of the membrane, while the other side was carefully unsealed. The small 220 
intestine fluid inside the membrane was carefully collected (≈8 mL), was subsequently 221 
combined with the remaining 70 mL from the incubation and stored at +4 o C prior to liquid-222 
liquid extraction (LLE).  223 
The transition between the small intestine and colon compartments was achieved by physical 224 
transfer: the dust was recovered from the 70 mL of small intestine media by centrifugation 225 
(3500 rpm, 15 min), then added to 70 mL of colon medium. Using the same RC membrane 226 
and Tenax TA® as in the small intestine compartment, approximately 8 mL of pre-warmed 227 
colon medium were added and sealed with the metallic clips as described for the stomach 228 
compartment, re-introduced into the bottle where the indoor dust was re-suspended using the 229 
colon medium and incubated for 16 h (Fig 1C). At the end of the colon incubation, the dust 230 
pellet was recovered by centrifugation as before and stored at -20 oC for extraction. Finally, 231 
Tenax TA® was recovered using clean cotton wool filtration, the colon fluid was passed 232 
through cotton wool, combined with the remaining 70 mL of colon fluid and stored at +4 oC 233 
for LLE (Fig SI-2). The cotton wool pieces from filtration together with the Tenax TA®, the 234 
RC membrane and the metallic clippers were collected in one bottle for ultra-sonication 235 
assisted extraction. More details on the RC membrane/ Tenax TA® system, Tenax TA® 236 
filtration and recovery are available at Fig. SI 1 and Fig.SI 2, respectively. 237 
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2.4 Tenax TA® sorption capacity 238 
An assessment of PBDE release via the gut and Tenax TA® sorption capacity with respect 239 
to the three CE-PBET compartments was conducted per batch (i.e. a single Tenax TA® 240 
sorption experiment was conducted separately relative to the CE-PBET compartment 241 
and its incubation duration), not in sequential mode (i.e. continuous Tenax TA® sorption; 242 
total incubation duration 21 h). Briefly, a fresh Tenax TA® sample (0.5 g) was incubated 243 
using a new RC dialysis membrane before the initiation of each CE-PBET compartment. 244 
Each Tenax TA® sample was finally harvested and subjected to extraction and clean up, 245 
along with the gut fluids and the residual dust as described in section 2.5.2. 5 Extraction 246 
and clean up  247 
Before extraction, all samples were spiked with 200 ng of internal standard (ISTD) mix (100 248 
μL of 2 ng/μL) prepared in toluene (BDE77 for BDE28, 47 and 100 and BDE128 for 249 
BDE153, 154 and 184 quantifications, respectively) and shaken on an orbital shaker for 1h. 250 
Gut fluids were subjected to a LLE using 30 mL hexane/ethyl acetate 3:1 v/v twice (Fig. SI2 251 
– step 1). Two mL of acetone were added to enhance separation, when necessary. A gel-like 252 
emulsion bilayer (mainly lipid and carbohydrates) was developed, especially in the colon 253 
compartment. Oven-baked Na2SO4 (400 
oC; powder) was added in the combined LLE 254 
extracts to absorb all remaining water residues and dissolve the gel-like emulsion. All 255 
samples were then allowed to settle for 1h at room temperature and the extracts were 256 
collected by centrifugation (3500 rpm, 15 min). The residual dust and the recovered Tenax 257 
TA® beads (together with the glass wool and the metallic clips) were subjected to ultra-258 
sonication assisted extraction for 15 min using 30 mL acetone/hexane 1:3 v/v twice (Fig. SI-2 259 
– step 2 & 3). After each step, the extracts were collected by centrifugation (3500 rpm, 15 260 
min). All extracts collected from each step were combined, evaporated to 1mL hexane using 261 
Syncore ® Analyst evaporator (Buchi, Switzerland) and then loaded onto Florisil® cartridges 262 
(2 g, 6 mL), using a slightly modified method published elsewhere (Van den Eede et al., 263 
2012) (Fig. SI 2 – step 4). Briefly, Florisil® cartridges were pre-cleaned with 10 mL ethyl 264 
acetate and 6 mL of hexane; our target analytes were eluted using 20 mL hexane. This eluate 265 
was further concentrated to 1mL (in hexane) and then subjected to SPE clean-up on 5% 266 
acidified silica (5% AS) (2 g, 6 mL). The 5% AS cartridges were pre-cleaned with 6 mL 267 
hexane and 3 mL dichloromethane and then all extracts from the Florisil® step were loaded 268 
onto the SPE silica column. Our target analytes were eluted using 16 mL hexane and 8 mL 269 
dichloromethane and after collection, all eluates were concentrated near dryness under a 270 
gentle stream of N2, reconstituted in 100 μL of toluene and then filtered using a micro 271 
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centrifuge filter lined with 0.45 μm pore size nylon filter (1.5 mL volume capacity) . Finally, 272 
the samples were transferred to injection vials, biphenyl (40 ng) was added as an injection 273 
recovery standard and analysed by GC-EI/MS. Further details about instrumental analysis are 274 
available at SI. 275 
2.6 Data analysis  276 
Bioaccessibility can be expressed as a mass (e.g. ng of a contaminant solubilised in the GI 277 
tract), a concentration (ng/g of a contaminant in dust) or as a fraction expressed in percentage 278 
(BAF%) (Guney and Zagury, 2016). In our study, bioaccessibility was determined according 279 
to (García-Alcega et al., 2016) using Eq. 1, where mass FR (SI+colon+Tenax TA®) is set as 280 
the sum of FR mass (ng) determined in small intestine (SI), colon and Tenax TA® 281 
compartments of CE-PBET system and mass FR (dust residual) is the FR mass (ng) 282 
determined in the dust residual collected after 16h-incubation of CE-PBET colon 283 
compartment which is considered as the non-bioaccessible fraction.  284 
𝐵𝑖𝑜𝑎𝑐𝑐𝑒𝑠𝑠𝑖𝑏𝑖𝑙𝑖𝑡𝑦 % (𝐵𝐴𝐹%)286 
=
𝑚𝑎𝑠𝑠 𝐹𝑅 (𝑆𝐼 + 𝐶𝑜𝑙𝑜𝑛 + 𝑇𝑒𝑛𝑎𝑥 TA®) 
𝑚𝑎𝑠𝑠 𝐹𝑅 (𝑆𝐼 + 𝐶𝑜𝑙𝑜𝑛 + 𝑇𝑒𝑛𝑎𝑥®) + 𝑚𝑎𝑠𝑠 𝐹𝑅 (𝑑𝑢𝑠𝑡 𝑟𝑒𝑠𝑖𝑑𝑢𝑎𝑙)
 𝑥 100 287 
 (Eq.1)  285 
GraphPad Prism® version 7.04 for Windows (GraphPad Software, La Jolla CA, USA) was 288 
used for statistical analysis. Prior to statistical analysis, all BAF% were converted into 289 
fractions and arc-sine transformed. This mathematical transformation is necessary for 290 
statistical analysis of results set in percentages in order to equalise variances among 291 
treatments (Sokal and Rohlf, 1995). Multiple t-tests (unpaired; p<0.05) were performed to 292 
assess statistically significant differences among the different Tenax TA® amounts added 293 
(sections 3.1 and 3.2), whereas ordinary two-way ANOVA (Uncorrected Fisher’s test, 294 
p<0.05) was performed to assess statistical differences for bioaccessibility with and without 295 
the addition of Tenax TA® in SRM 2585 method validation (section 3.3).  296 
2.7 Quality assurance and quality control 297 
All samples were analysed in triplicate together with oven-baked, laboratory-grade sand 298 
(procedural blank) and SRM 2585 (n=3, NIST, USA) was used for method validation and QC 299 
testing. Concentrations of our target analytes in method blanks were all below method limit 300 
of detection (mLOD) (0.05 ng/μL). RC membrane and Tenax TA® blanks were extracted for 301 
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FR background contamination prior use and all values were found below mLOD. No weight 302 
correction on bioaccessibility values with respect to potential Tenax TA® mass losses was 303 
employed in our study. According to the ISO 16751 method on organic pollutant 304 
bioavailability (2015), correction for such losses is recommended by air drying and weighing 305 
the dry amount of Tenax TA® after extraction (ISO, 2015). In our study separating Tenax 306 
TA® beads from the glass wool and the RC membrane post extraction was not feasible due to 307 
the character of Tenax TA® to adhere in any surface it comes in contact with during filtration 308 
(e.g. glass wool).Extraction efficiency (%) was assessed for SI, colon, Tenax TA® and 309 
residual dust compartments by spiking experiments (see SI Table 2). Briefly, 100 ng of native 310 
PBDEs (100 μL of 1 ng/μL) in iso-octane were spiked to SI and colon media, Tenax TA® 311 
(0.5 g) and dust (0.5 g). All samples were shaken on an orbital shaker for 1h. Finally, 30 mL 312 
of the corresponding extraction medium was added in each compartment, following the same 313 
sample preparation processes as before. Finally, biphenyl (40ng) was added as an injection 314 
recovery standard and the samples were analysed by GC-EI/MS. Extraction efficiency values 315 
for all target analytes were >60% in all CE-PBET compartments, except BDE100 efficiency 316 
which was 52% and 54% in Tenax TA® and residual dust, respectively. Such phenomena 317 
may be attributed to potential mass loses of Tenax TA® during glass wool filtration steps. 318 
Despite the moderately lower extraction efficiency for BDE100 in comparison to the other 319 
target analytes, the relative standard deviation (RSD%) of the method for BDE100 was 6%. 320 
Given the low deviation and variability, no correction was performed for BDE100 (Table SI 321 
3). Glass test tubes were cleaned by soaking for at least 12 h in an alkali solution. After 322 
washing, the tubes were rinsed with water and dried at 100 ºC for at least 12 h and burnt at 323 
400°C to remove all traces of contamination. 324 
3. Results and discussion 325 
3.1 Tenax TA® optimisation 326 
The addition of Tenax TA® in CE-PBET considerably increased the bioaccessible fraction 327 
(%BAF) of all target analytes, illustrating the value of Tenax TA® as an adsorbent matrix for 328 
HOCs. Different masses of Tenax TA® were added to the CE-PBET system to optimise the 329 
adsorbent sink to ensure exhaustive FR desorption from indoor dust. PBDE-spiked indoor 330 
dust samples (n=3) were tested under four different conditions; (A) without any Tenax TA® 331 
addition (control) and with three different amounts of Tenax TA®, namely 0.25 g (B), 0.5 g 332 
(C) and 0.75 g (D). The same length of RC dialysis membrane (16cm) and mass of dust (0.5 333 
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g) was used in all treatments. Our results show that Tenax TA® enhanced gut bioaccessibility 334 
for PBDEs by approximately two-fold (Fig. 2) and the bioaccessible fraction was 335 
significantly different (p<0.001) between the controls (no Tenax) and with Tenax TA® 336 
addition, for all target analytes (Fig. 2). For example, with no Tenax TA® (control), the 337 
bioaccessible fraction of the low brominated PBDEs, BDE28 and BDE47, was 37.7% and 338 
32.8%, respectively, whereas their BAF% increased with 0.25 g Tenax TA® inclusion to 339 
55.1% and 54.9%, respectively. A trend to decreasing BAF% with increasing degrees of 340 
bromination for PBDEs can be seen for the control treatments and the different amounts of 341 
Tenax (Fig 2). Such findings are in agreement with Fang and Stapleton (2014), where a 342 
negative relationship between gut bioaccessibility and PBDE physicochemical properties 343 
such as degrees of bromination, MW and log Kow was described (Fang and Stapleton, 2014). 344 
Few studies describe the influence of Tenax TA® inclusion on gut bioaccessibility of organic 345 
pollutants from solid matrices such as indoor dust or soil. CE-PBET and Tenax TA® were 346 
employed to assess FR gut bioaccessibility and for a wide range of low and high MW FRs 347 
present in indoor dust including BDE47, BDE100 and BDE183; in their experimental design, 348 
Fang and Stapleton (2014) used 0.5 g of Tenax as an absorptive sink but the effects of 349 
varying Tenax TA® content were not reported (Fang and Stapleton, 2014). In a study 350 
assessing PAHs bioaccessibility in soils from China, 0.25 g of Tenax TA® were added into a 351 
PBET in vitro system (Li et al., 2015). According to Li et al (2015), this mass was five-fold 352 
higher than the small intestine organic matter (OC), thus allowing sufficient sorption capacity 353 
for the PAHs mobilized during their study (Li et al., 2015). Zhang et al (2017) reported fast 354 
and efficient sorption only for high MW PAHs (i.e. 3 -5 benzene ring) using 0.1 g of Tenax 355 
TA® studying PAH soil bioaccessibility; poor extraction efficiencies were noted for volatile 356 
PAHs such as naphthalene, acenaphthylene and acenaphthene, possibly as a result of an air 357 
drying step during Tenax TA® collection and separation from the gut fluid (Zhang et al., 358 
2017). Varying the content of Tenax TA® (0.25, 0.5 and 0.75 g) in the CE-PBET system 359 
studied here, showed few statistically significant differences for our analyte recoveries. Here, 360 
statistically significant differences among the three Tenax TA® amounts tested were found 361 
only for BDE28 bioaccessibility as an exception; some increase in BDE28 BAF% with Tenax 362 
TA® content, rising from 55.1% with 0.25 g Tenax TA® to 66.7% with 0.5 g (0.25 g vs 0.5 g; 363 
p=0.017) and 69.9% with 0.75 g Tenax TA® added (0.25 g vs 0.5 g; p=0.006) was observed. 364 
These results reflect the physicochemical properties of this FR as a low MW tri-BDE 365 
congener; Tenax TA® is a hydrophobic sink and the calculated log Kow (EpiWeb) shows that 366 
BDE28 (log Kow 5.88) is less hydrophobic than BDE47 (log Kow 6.77) and hence greater 367 
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amounts of the adsorbent may be needed to capture all of the released BDE28. For all other 368 
analytes, there were no statistically significant differences in BAF% among the varying 369 
Tenax TA® amounts tested. In other words, for BDE28 being the least hydrophobic of our 370 
target analyte list, we propose that Tenax TA mass loading greater than 0.25 g is required in 371 
order maximise the sortion potentialof low MW PBDEs such as BDE28 to Tenax TA®.   372 
Given the a) high sorption capacity of Tenax TA®, b) the broad range of physical properties 373 
(MW, water solubility and log Kow) of our FRs mobilised from the ingested matrix and c) the 374 
relatively high Tenax TA® mass recovery (SI Fig 3), 0.5 g of Tenax TA® were selected and 375 
subsequently used below. Our results show that in order to maintain a constant sorptive 376 
gradient for the low MW PBDEs, a larger mass of Tenax TA® is required, since 0.25 g of 377 
Tenax TA® was not enough to sustain an exhaustive in vitro gut extraction for all target 378 
analytes.  379 
3.2 Tenax TA® sorption capacity to PBDEs in CEPBET components 380 
 381 
Here the influence of the gut media on Tenax sorption was being tested. Each compartment 382 
(i.e. stomach, small intestine colon) was tested independently so Eq. 1 was not suitable for 383 
calculating PBDE sorption capacity on the different Tenax TA® batches. Hence, Eq.1  was to 384 
determine the Tenax® loadings as fractions of the total concentration in each CE-PBET 385 
compartment PBDE sorption capacity (%) was determined using equation 2 (Eq. 2), where 386 
mass FR in Tenax TA® is the FR mass (ng) determined in each Tenax TA® sample for each 387 
CE-PBET compartment and mass FR in compartment is FR mass (ng) determined in CE-388 
PBET gut fluids separately.  389 
𝑇𝑒𝑛𝑎𝑥 𝑆𝑜𝑟𝑝𝑡𝑖𝑜𝑛 (%) =
mass FR in Tenax TA® 
𝑚𝑎𝑠𝑠 𝐹𝑅 in Tenax TA® +𝑚𝑎𝑠𝑠 FR in compartment
 𝑥 100  (Eq. 2) 390 
Shown in figure 3 are the results from PBDEs sorption to Tenax TA® in the three different 391 
CE-PBET compartments with respect to their incubation step. PBDE sorption to Tenax TA® 392 
results should not be considered as total PBDE bioaccessibility, but as the component 393 
attributable to Tenax TA® as an absorptive sink. Within the stomach compartment, BDE28 394 
and BDE47 presented higher sorption on Tenax TA® (43.7 % and 25.6%, respectively) 395 
compared to PBDEs with higher bromine content such as BDE154 and BDE183 where Tenax 396 
TA® sorption ranged from 7.0 % to 8.8 %, respectively. Comparing stomach and colon 397 
absorption, statistically significant relationships (p<0.01) were noted for all target analytes, 398 
apart from BDE28 and BDE47 (p>0.05). Fundamental differences between stomach and 399 
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colon media formulae, ingredient concentrations (Table SI 3) and incubation times can be 400 
considered as the driving factors for the interpretation of such results.  Small intestine 401 
absorption to Tenax TA® was similar to the colon  for BDE28 (66.2 % and 60.0  %, 402 
respectively, whereas it was found repeatedly lower than the colon for all the other target 403 
analytes (Fig. 3) without any considerable differences. Tenax TA®  sorption in the colon was 404 
higher than SI overall, but was not statistically significant for individual compounds  405 
exceptBDE183 sorption on Tenax TA® which was nearly two-fold higher in the colon in 406 
comparison to small intestine (52.6 % and 36.1 %, respectively, p=0.045). We believe that 407 
such findings are influenced by the addition of food components and bile salts as surfactants 408 
to the small intestine and colon compartments (Table SI 3). Such biological phenomena are 409 
able to enhance FR solubility and desorption potential from the dust to the gut (i.e. more 410 
released and freely available FR in the gut fluids), promoting thus higher FR mobilisation and 411 
sorption onto the Tenax TA sink (Oomen et al., 2004; Zhang et al., 2015).  Compared to the 412 
small intestine, incubation times and the concentration of compounds enhancing desorption 413 
(e.g. mucin) are higher in the colon. All these factors combine to increase the release from the 414 
dust that a higher concentration of PBDE is in solution and hence available for subsequent 415 
sorption onto Tenax TA® .Hence, both the “solvent” capacity of the medium and the “sink” 416 
capacity of the Tenax TA® are required to achieve optimum extraction of FRs from dust as a 417 
matrix. Besides Tenax TA®, our results further support the idea of dietary components 418 
addition in CE-PBET acting as additional mechanism enhancing FR mobilisation, especially 419 
in the lipid-rich colon compartment as reported by (Tilston et al., 2011). 420 
3.3 Method performance using SRM 2585 421 
The selected CE-PBET parameters as well as the overall performance of our new method 422 
were assessed using SRM 2585 serving as a well-characterised and homogenous dust sample.  423 
PBDE bioaccessibility was studied using a) CE-PBET without the Tenax TA® adsorption 424 
sink, b) CE-PBET with the addition of 0.5 g of Tenax TA® and c) PBDE-spiked SRM 2585 425 
(100 ng spike) to evaluate greater FR contamination levels under environmentally realistic 426 
conditions using SRM 2585 as the same homogenous dust sample. As observed for BAF% 427 
using a dust sample from Reading (section 3.1), statistically significant differences (p=0.03) 428 
were found in %BAF% for all target analytes when comparing CE-PBET without Tenax TA® 429 
addition (Fig. 4 A) and with Tenax TA® addition (Fig 4 B & C).  The BAF% when  Tenax 430 
TA® was used as an adsorption sink rerose between approximately two-fold (BDE153 and 431 
BDE183) with greater increases seen for the low-brominated and less hydrophobic FRs such 432 
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as BDE28 and BDE47 (nearly 3-fold bioaccessibility increases, respectively) (Fig. 4 B & C). 433 
No statistically significant effect (p>0.05) was found between the two SRM 2585 treatments 434 
(spiked and non-spiked) which both included 0.5 g of Tenax TA® and different FR 435 
contamination levels did not present any considerably different bioaccessibility values from 436 
the same dust matrix (Fig. 4 B & C). Finally, compared to the control treatments (i.e. no 437 
Tenax TA inclusion), the performance of the novel CE-PBET method described here using 438 
SRM 2585 offers two to three-fold gut bioaccessibility increase for a wide range of PBDEs 439 
with diverse physicochemical profiles, following a similar pattern to the indoor dust tested in 440 
section 3.1.  441 
3.4 Proposing a unified test approach  442 
This study describes an efficient method to physically separate Tenax TA® as an absorbent 443 
sink and indoor dust for in vitro bioaccessibility testing, and our model allows assessment of 444 
FRs (and potentially other HOCs) bioaccessibility from a solid matrix using artificial gastro-445 
intestinal fluids. Previous methods used a self-designed stainless steel sieve to separate and 446 
recover Tenax TA® beads (Fang and Stapleton, 2014; ISO, 2015; Li et al., 2015, 2016).  Our 447 
approach, using RC dialysis tubing provides some important benefits.  Dialysis tubing is 448 
readily available, reproducible (quality controlled) and can be sourced with a wide range of 449 
molecular weight cut offs. This allows investigators to select a membrane with a MW cut off 450 
sufficient to permit free diffusion of the analytes of interest, whilst restricting passage of 451 
larger macromolecules such as enzymes or proteins that may be added to simulated GI fluids. 452 
By restricting the passage of these unwanted materials, the sorption capacity of the Tenax 453 
TA® is predominantly used for the organic pollutants rather than media components and clean 454 
up and desorption is thus simplified.  The tubing functions effectively to physically separate 455 
the Tenax TA® from the solid matrix (dust) and has high pH and temperature tolerance. Our 456 
study also shows the benefits of using an adsorption sink in the CE-PBET system. Compared 457 
to controls with no Tenax TA®, inclusion of the resin increased gut bioaccessibility for 458 
PBDEs with diverse physicochemical profiles. For the low brominated BDE28, 0.25 g of 459 
Tenax TA® were insufficient for exhaustive in vitro gut absorption, illustrating that the 460 
amount of Tenax TA® added to the modified CE-PBET system should be optimized with 461 
respect to the physicochemical properties (e.g. LogKow, water solubility) of the target 462 
analytes tested. Other than BDE28, for the (hydrophobic) FR’s studied here, 0.5 g of Tenax 463 
TA® was shown to be an appropriate amount to add in order to ensure released pollutants 464 
were readily adsorbed. A proposed rule can be a Tenax TA® mass loading of 0.5 g for 465 
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organic compounds with LogKow < 6 (e.g. BDE28, low MW PAHs etc.), while 0.25 g of 466 
Tenax TA® mass loading can be employed for very lipophilic compounds such as penta- and 467 
octa- BDEs (LogKow > 6).   468 
3.5. Future work  469 
Given the assumption that first-order permeability rates can be obtained provided that the RC 470 
tubing system is well stirred and the gut fluid is changed several times during the dialysis 471 
procedure, no kinetic characterisation was conducted in the present study. However, we 472 
believe that further kinetic characterisation of the diffusion rates of the RC membrane system 473 
should be encouraged and explored in the future. Additionally, the proposed unified gut 474 
bioaccessibility method should be further examined against different matrices (e.g. soil) and 475 
groups of emerging organic pollutants with diverse physicochemical properties. Fang and 476 
Stapleton (2014) proposed their method to be employed for flame retardants with log Kow>5 477 
using 0.5 g of Tenax TA® mass loading in the test settings. Additionally, the ISO method on 478 
bioavailability was designed for non-polar organic compounds with log Kow>3 (ISO, 2015). 479 
Potentially, our unified method on in vitro gut bioaccessibility could be proposed to a wide 480 
range of organic pollutants and a rule of Tenax TA® mass loading could be established with 481 
respect to a pollutant’s log Kow and water solubulity values, e.g. 0.25 g of Tenax TA® mass 482 
loading should be used when testing for compounds with log Kow greater than 6 (i.e. more 483 
hydrophobic), whereas 0.5 g of Tenax TA® mass should be employed for organic compounds 484 
with log Kow lower than 6. Given the infinite sink inclusion, bioaccessibility parameters 485 
including a reduction of the S/L ratio could be potentially explored on the basis of mass 486 
transfer from the outside to inside of the membrane being quicker since the concentration 487 
outside would reach earlier the solubility limit. 488 
3.6 Conclusion  489 
Under the influence of the ISO 16751 method on the environmental availability of non-polar 490 
compounds being currently approved for registration, we propose a novel test format for 491 
assessing in vitro bioaccessibility of PBDEs with Tenax TA® addition as an adsorptive sink. 492 
Our data also show that the existing default assessment of risk (i.e. all the ingested pollutant 493 
in a solid matrix being bioavailable) is an overestimate and that the BAF% varies between 494 
~60% (BDE47) and ~50% (BDE153).  This study reveals that colon sorption to Tenax TA® 495 
for low MW BDEs was similar compared to small intestine sorption for BDE28, unlike other 496 
more hydrophobic PBDEs where colon sorption was higher than small intestine sorption. 497 
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Well designed in vitro bioaccessibility tests thus provide a simple approach for initial human 498 
risk assessments from ingested solid matrices giving a conservative, yet realistic indication of 499 
risk. 500 
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Artwork and Tables with Captions 697 
 698 
Figure 1 – Schematic representation of CE-PBET gut compartments and parameters (i.e. stomach (1 h, pH = 2.5), small intestine (SI) (4 h, pH = 7) 699 
and colon (16 h, pH = 6.5)) using 0.5 g Tenax TA® added in 16 cm of RC dialysis membrane. 700 
25 
 
 701 
Figure 2 – CE-PBET bioaccessibility fraction (%BAF) of PBDEs without any Tenax TA® addition (control, A) and CE-PBET with Tenax TA® 702 
addition in three different amounts; i.e. 0.25 g (B), 0.5 g (C) and 0.75 g (D). Statistically significant differences shown here (**; p<0.01 and ***; 703 
p<0.001) were established between the control (A) and all Tenax TA® treatments (B, C, D). Bar charts represent average values of triplicates. Error 704 
bars represent one standard deviation.  705 
 706 
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 712 
Figure 3 – Line plots presenting FR sorption on Tenax TA®  separately in stomach (1h), small intestine (SI; 4h) and colon (16h) compartments. Line plots 713 
represent average values of triplicates. Error bars represent one standard deviation. 714 
  715 
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 716 
 717 
Figure 4 – Method performance of CE-PBET and bioaccessibility fraction (%BAF) using SRM 2585 without Tenax TA® inclusion (control; A), with Tenax 718 
TA® inclusion (B) and artificially spiked SRM 2585 and Tenax TA® inclusion (C). Statistically significant differences shown here (*; p<0.05, **; p<0.01 and 719 
***; p<0.001) were established between control treatments of SRM 2585 without Tenax TA® inclusion (A)  and treatments B and C with Tenax TA® inclusion . 720 
Bar charts represent average values of triplicates. Error bars represent one standard deviation.  721 
 722 
 723 
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